Market Overview:
The global Duchenne muscular dystrophy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness about the disease, and advancements in treatment options. Based on type, the global Duchenne muscular dystrophy market is segmented into deflazacort, prednisone, and others. Prednisone is expected to account for a major share of the global Duchenne muscular dystrophy market due to its high efficacy in treating symptoms associated with the disease. Based on application, male patients are more commonly affected by Duchenne muscular dystrophy as compared female patients. However, with advancements in treatment options such as gene therapy and stem cell therapy, female patients are increasingly being diagnosed with this condition.
Product Definition:
Duchenne muscular dystrophy is a rare, genetic disorder that primarily affects boys. It causes muscle weakness and progressive loss of muscle function. Duchenne muscular dystrophy is the most common type of muscular dystrophy.
Deflazacort:
Deflazacort is a corticosteroid used in the treatment of muscular dystrophy, primarily Duchenne Muscular Dystrophy (DMD). It was developed by Roche and first marketed in the U.S. as Aldurazyme in 2002. The drug’s brand name was changed to Deflazacort by AstraZeneca in 2010, after it acquired the generic rights to deflazacort from RoCa Pharmaceuticals Inc.
Prednisone:
The drug prednisone is used to treat a wide range of conditions such as bronchitis, asthma, and inflammation. It is also used in the treatment of some skin diseases like eczema. The main function of this drug is to reduce swelling and allergic reactions by blocking certain immune cells that are responsible for causing them. Prednisone works by decreasing the production of inflammatory cytokines (substances that cause inflammation).
Application Insights:
The male application segment held the largest share of more than 60.0% in 2017. The high prevalence of male patients suffering from dMD is primarily due to the fact that most of them are diagnosed at a very early stage and are therefore, treated with steroids which results in higher market penetration for this product category among males compared to females.
Duchenne muscular dystrophy affects mostly boys, however; there are also cases reported where the disease has been diagnosed in girls as young as two years old. It is an X-linked disorder which means it predominantly occurs among males and only 10% of all cases have been reported globally so far have been observed in females along with their brothers who suffer from dMD.
Regional Analysis:
North America dominated the market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its large share. In addition, rising awareness about dMDD is anticipated to fuel market growth during the forecast period.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to a rise in disposable income and improving healthcare infrastructure coupled with growing awareness about Duchenne muscular dystrophy treatment options among patients & their families as well as physicians & surgeons across countries such as India China Japan Australia Singapore Thailand Malaysia Indonesia Philippines Vietnam South Korea Brazil etc.
Brazil was one of the largest markets in Latin America region due to high prevalence rate along with favorable government initiatives that provide financial assistance for DMD drugs leading towards quality life expectancy.
Growth Factors:
- Increasing prevalence of Duchenne Muscular Dystrophy (DMD) due to genetic mutations
- Growing awareness about DMD among people and healthcare professionals
- Rising number of clinical trials for the treatment of DMD
- increasing investment by pharmaceutical companies in the development of new therapies for DMD
- Government initiatives and funding for research on Duchenne Muscular Dystrophy
Scope Of The Report
Report Attributes
Report Details
Report Title
Duchenne Muscular Dystrophy Market Research Report
By Type
Deflazacort, Prednisone, Others
By Application
Male, Female
By Companies
PTC Therapeutics, Sarepta Therapeutics, Others
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Duchenne Muscular Dystrophy Market Report Segments:
The global Duchenne Muscular Dystrophy market is segmented on the basis of:
Types
Deflazacort, Prednisone, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Male, Female
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- PTC Therapeutics
- Sarepta Therapeutics
- Others
Highlights of The Duchenne Muscular Dystrophy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Deflazacort
- Prednisone
- Others
- By Application:
- Male
- Female
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Duchenne Muscular Dystrophy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Duchenne Muscular Dystrophy is a rare genetic disorder that affects the muscles and causes them to become weak and eventually die. The disease usually starts to show signs during childhood, but can also occur in adults.
Some of the major players in the duchenne muscular dystrophy market are PTC Therapeutics, Sarepta Therapeutics, Others.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Duchenne Muscular Dystrophy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Duchenne Muscular Dystrophy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Duchenne Muscular Dystrophy Market - Supply Chain
4.5. Global Duchenne Muscular Dystrophy Market Forecast
4.5.1. Duchenne Muscular Dystrophy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Duchenne Muscular Dystrophy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Duchenne Muscular Dystrophy Market Absolute $ Opportunity
5. Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
5.3.1. Deflazacort
5.3.2. Prednisone
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
6.3.1. Male
6.3.2. Female
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Duchenne Muscular Dystrophy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Duchenne Muscular Dystrophy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Duchenne Muscular Dystrophy Demand Share Forecast, 2019-2026
9. North America Duchenne Muscular Dystrophy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
9.4.1. Male
9.4.2. Female
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
9.7.1. Deflazacort
9.7.2. Prednisone
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Duchenne Muscular Dystrophy Demand Share Forecast, 2019-2026
10. Latin America Duchenne Muscular Dystrophy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
10.4.1. Male
10.4.2. Female
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
10.7.1. Deflazacort
10.7.2. Prednisone
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Duchenne Muscular Dystrophy Demand Share Forecast, 2019-2026
11. Europe Duchenne Muscular Dystrophy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Duchenne Muscular Dystrophy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
11.4.1. Male
11.4.2. Female
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
11.7.1. Deflazacort
11.7.2. Prednisone
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Duchenne Muscular Dystrophy Demand Share, 2019-2026
12. Asia Pacific Duchenne Muscular Dystrophy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Duchenne Muscular Dystrophy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
12.4.1. Male
12.4.2. Female
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
12.7.1. Deflazacort
12.7.2. Prednisone
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Duchenne Muscular Dystrophy Demand Share, 2019-2026
13. Middle East & Africa Duchenne Muscular Dystrophy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Duchenne Muscular Dystrophy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Duchenne Muscular Dystrophy Market Size and Volume Forecast by Application
13.4.1. Male
13.4.2. Female
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Duchenne Muscular Dystrophy Market Size and Volume Forecast by Type
13.7.1. Deflazacort
13.7.2. Prednisone
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Duchenne Muscular Dystrophy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Duchenne Muscular Dystrophy Market: Market Share Analysis
14.2. Duchenne Muscular Dystrophy Distributors and Customers
14.3. Duchenne Muscular Dystrophy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. PTC Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sarepta Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Others
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
